{"id":"insulin-lispro-mix-25","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a premixed insulin formulation containing 25% insulin lispro (rapid-acting) and 75% insulin lispro protamine suspension (intermediate-acting). Insulin lispro is a recombinant human insulin analog with a faster onset and shorter duration than regular human insulin. The mixture allows for both immediate postprandial glucose control and basal coverage, mimicking physiologic insulin secretion patterns.","oneSentence":"Insulin lispro mix 25 is a rapid-acting insulin analog combined with intermediate-acting insulin that binds to insulin receptors to facilitate glucose uptake and utilization in cells.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:16:24.155Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT03547427","phase":"NA","title":"Glucagon Counterregulation in Type 1 Diabetes","status":"TERMINATED","sponsor":"University of Virginia","startDate":"2018-05-20","conditions":"Type 1 Diabetes Mellitus","enrollment":13},{"nctId":"NCT04023344","phase":"PHASE3","title":"Efficacy and Safety of Insulin Lispro Biphasic 25 Compared to Humalog® Mix 25 in Type 2 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2018-03-14","conditions":"Diabetes Mellitus, Type 2, Diabetes Mellitus","enrollment":210},{"nctId":"NCT03606018","phase":"NA","title":"A Study to Compare Pharmacokinetics and Pharmacodynamics of Insulin Lispro Mix 25 to Humalog® Mix 25 in Healthy Subjects","status":"COMPLETED","sponsor":"Geropharm","startDate":"2017-04-12","conditions":"Clamp Study","enrollment":48},{"nctId":"NCT03320031","phase":"PHASE4","title":"A Study of Adding Linagliptin to Control Glycemic Variability and HbA1c in Peritoneal Dialysis Patients With Type 2 Diabetes(PDPD) With Premixed Insulin Therapy","status":"UNKNOWN","sponsor":"Yanbing Li","startDate":"2017-06-03","conditions":"Type 2 Diabetes Mellitus, Peritoneal Dialysis","enrollment":232},{"nctId":"NCT02212951","phase":"PHASE1, PHASE2","title":"Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500","status":"COMPLETED","sponsor":"Biodel","startDate":"2014-05","conditions":"Type 2 Diabetes Mellitus","enrollment":12},{"nctId":"NCT02324309","phase":"PHASE1, PHASE2","title":"BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance","status":"COMPLETED","sponsor":"Biodel","startDate":"2014-05","conditions":"Diabetes Mellitus","enrollment":12},{"nctId":"NCT02514954","phase":"PHASE1","title":"Postprandial Blood Glucose Control With BioChaperone® Combo and Insulin Lispro (Humalog®) Mix 25 in People With Type 1 Diabetes Mellitus","status":"COMPLETED","sponsor":"Adocia","startDate":"2015-07","conditions":"Type 1 Diabetes Mellitus","enrollment":28},{"nctId":"NCT01773473","phase":"PHASE4","title":"Comparison of Insulin Mix25 Versus Mix50","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2013-01","conditions":"Type 2 Diabetes Mellitus","enrollment":403},{"nctId":"NCT01175824","phase":"PHASE4","title":"Comparison of the Efficacy and Safety of Two Insulin Intensification Strategies","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-04","conditions":"Diabetes Mellitus, Type 2","enrollment":478},{"nctId":"NCT01175811","phase":"PHASE4","title":"A Study Comparing Insulin Intensification Therapies in Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":402},{"nctId":"NCT01147627","phase":"NA","title":"Effect of Different Interventions on Glycemic Control and β-cell Function in Newly Diagnosed Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Sun Yat-sen University","startDate":"2010-08","conditions":"Diabetes Mellitus, Type 2, Newly Diagnosed","enrollment":416},{"nctId":"NCT01398670","phase":"PHASE3","title":"Immunogenicity Study of Wockhardt's Insulin Lispro/Lispro Mix Basal Bolus Regimen in Type 1 Diabetics","status":"WITHDRAWN","sponsor":"Wockhardt","startDate":"2012-02","conditions":"Type I Diabetes","enrollment":""},{"nctId":"NCT01400802","phase":"PHASE1","title":"Comparative Bioequivalence Study of Wockhardt's Insulin Analogue Mixture Listro Mix 75/25® and Humalog Mix75/25 ® in Healthy Subjects","status":"WITHDRAWN","sponsor":"Wockhardt","startDate":"2011-11","conditions":"Bioequivalence in Healthy Subjects","enrollment":""},{"nctId":"NCT01336751","phase":"PHASE3","title":"Lantus Versus Humalog Mix as add-on Therapy in Type Diabetes Patients Failing Sulfonylurea and Metformin Combination Treatment","status":"COMPLETED","sponsor":"Sanofi","startDate":"2001-07","conditions":"Diabetes Mellitus, Type 2","enrollment":212},{"nctId":"NCT01303042","phase":"NA","title":"Efficacy of Insulin Lispro Mix 50/50 Therapy","status":"UNKNOWN","sponsor":"Aichi Gakuin University","startDate":"2011-02","conditions":"Diabetes Mellitus, Type 2","enrollment":80},{"nctId":"NCT00279201","phase":"PHASE4","title":"The DURABLE Trial: Evaluating the Durability of Starter Insulin Regimens in Patients With Type 2 Diabetes (IOOV)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2005-12","conditions":"Diabetes Mellitus, Type 2","enrollment":2091},{"nctId":"NCT00551538","phase":"PHASE4","title":"24 Hour Plasma Glucose Profiles Comparing Lispro Mix 75/25 vs. Glargine","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2003-05","conditions":"Type 2 Diabetes","enrollment":15},{"nctId":"NCT00135941","phase":"PHASE3","title":"Insulin Glargine Plus Insulin Glulisine Multiple Daily Injections (MDI) Versus Premix Insulin Treatment in Subjects With Diabetes Mellitus (Type 1 or Type 2)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-08","conditions":"Diabetes Mellitus","enrollment":582},{"nctId":"NCT00551356","phase":"PHASE3","title":"Lispro Mix 25 vs. Glargine in Type 2 Diabetics","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2002-11","conditions":"Diabetes Mellitus Type 2","enrollment":53}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Humalog Mix25","insulin lispro biphasic"],"phase":"phase_3","status":"active","brandName":"Insulin lispro mix 25","genericName":"Insulin lispro mix 25","companyName":"Eli Lilly and Company","companyId":"eli-lilly","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Insulin lispro mix 25 is a rapid-acting insulin analog combined with intermediate-acting insulin that binds to insulin receptors to facilitate glucose uptake and utilization in cells. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}